Series A
funding.
We have started Series A investment to accelerate our mission of making universal blood a reality. Every euro is directed toward bringing our platform from the lab to the clinic.
Clinical Trials & Hospital Operations
Funding Phase II and Phase III studies and the on‑site clinical operations needed to deploy ICHOR‑1 across partner hospitals.
Regulatory & Quality
Building the regulatory and quality systems required for FDA, EMA and global filings, including GMP compliance across our platform.
Hardware, Automation & Infrastructure
Scaling our closed‑loop bioreactor into a modular, GMP‑compliant manufacturing system ready for hospital deployment.
IP & Technology Security
Expanding our patent portfolio and securing the proprietary processes and data that protect our long‑term technology advantage.
Key Talent & Expansion
Recruiting world‑class glycoengineers, bioprocess engineers and clinical leaders to expand the team and accelerate the roadmap.